Caris Life Sciences (CAI) revenue breakdown
By product, Cost of services - Molecular profiling services is the largest at 94% of fiscal 2025 revenue, growing 66% a year over 2 years.
By region, United States is the largest at 99% of fiscal 2025 revenue, growing 65% a year over 2 years.
Revenue by product
Fiscal years, as Caris Life Sciences reports them in its 10-K filings; fiscal 2025 total $812M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Cost of services - Molecular profiling services | $279M | $349M | $767M | 94% |
| Cost of services - Pharma research and development services | $27M | $63M | $45M | 6% |
Revenue by region
Fiscal years, as Caris Life Sciences reports them in its 10-K filings; fiscal 2025 total $812M.
| Regions | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| United States | $293M | $402M | $801M | 99% |
| International | $13M | $10M | $11M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CAI.
Open CAI in InvestinglyQuestions
Where does Caris Life Sciences make its money?
In fiscal 2025, by product: Cost of services - Molecular profiling services $767M, Cost of services - Pharma research and development services $45M.
From Caris Life Sciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.